AzTrials
AzTrials

PediatricsNCT07035184

A Comparative Study Between Age-Based and Weight-Based Bupivacaine Dosing for Pediatric Spinal Anesthesia in Children Undergoing Elective Infra-Umbilical Surgeries

A study testing Spinal Anesthesia with Bupivacaine in people with Pediatrics and Spinal Aneshtesia, run by Cairo University at 1 site in Egypt.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This prospective randomized double-blinded controlled trial will include 60 pediatric patients aged 1 - 6 years old, both sexes, with American society of anesthesiologists (I and II) and undergoing elective infra-umbilical surgeries with anticipated duration ≤ 90 minutes. Read more about this study

Who is it for?
Ages 1 year to 6 years
What is being tested?
Spinal Anesthesia with Bupivacaine
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteEgypt
Study dates
1 Aug 2025to 15 Oct 2025
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 year to 6 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Children aged 1-6 years
  • Both genders.
  • American Society of Anesthesiologists (ASA) physical status I or II.
  • Elective infra-umbilical surgeries with anticipated duration ≤ 90 minutes.

Who cannot join

  • Guardian refusal.
  • Children with significant congenital heart disease (e.g., septal defects requiring surgical intervention)
  • Children with neuromuscular disorders or high intracranial pressure.
  • Children with spinal deformities or morbid obesity (body mass index (BMI) above the 99th percentile).
  • Children with a history or family history of coagulation disorders.
  • Children with local infection at the site of skin puncture for spinal anesthesia.
Show all 9Show fewer
  • Children with known allergy to Bupivacaine.
  • Surgeries requiring Trendelenburg or prone position.
  • Unexpected prolongation of surgery > 90 minutes

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Egypt1 site
  • Abu Elreesh Pediatric Hospital

    Cairo, Assida Zainab, 12211

    Hany M. El-Hadi Mohammed, MD, +201003066806, oblfollower_2001@yahoo.com, hany.elhadi@kasralainy.edu.eg

Other trials in Egypt

About this study

Official title: A Comparative Study Between Age-Based and Weight-Based Bupivacaine Dosing for Pediatric Spinal Anesthesia in Children Undergoing Elective Infra-Umbilical Surgeries: A Randomized Double-Blinded Controlled Trial

This prospective randomized double-blinded controlled trial will include 60 pediatric patients aged 1 - 6 years old, both sexes, with American society of anesthesiologists (I and II) and undergoing elective infra-umbilical surgeries with anticipated duration ≤ 90 minutes. Patients will be randomly divided into two equal groups: Weight-based dosing (Group A) and age-based dosing group (Group B). Both groups will receive hyperbaric bupivacaine 0.5%. The aim of the study is to evaluate the effectiveness of using age based dosing of Bupivacaine compared with standard method of weight based dosing in pediatric spinal anesthesia.

Read the detailed description

This prospective randomized double-blinded controlled trial will be conducted on 60 pediatric patients who will undergo elective infra-umbilical surgeries, e.g., inguinal hernia repair, orchiopexy, etc. admitted to the operating theatres of Abu El Reesh Children's Hospital, Cairo University.

Randomization and blinding An online randomization program (http://www.randomizer.org) will be used to generate a random list, and each patient's code will be kept in an opaque sealed envelope. Patients will be randomly allocated in a 1:1 allocation ratio into two equal groups in a parallel manner:

  • Group A (n=30): Children will receive spinal anesthesia according to weight-based dosing calculation of bupivacaine
  • Group B (n=30): Children will receive spinal anesthesia according to age-based dosing calculation of bupivacaine. The patient and/or related guardian will be blinded to group assignment as well as the anesthesiologist involved in data collection and analysis. A physician who is not involved in the study prepared the interventional medications.

Methods:

All patients will be subjected to the followings:

  1. History taking and demographic data collection (age, sex, weight, and ASA).
  2. Complete clinical examination.
  3. Routine Laboratory investigations

All patients will be instructed to fast according to the following guidelines:

2 hours for clear fluids, 4 hours for breastmilk, 6 hours for formula milk and other particulate fluids. EMLA cream (5%) will be applied to the anticipated puncture sites for IV cannulation and covered for 45 minutes before transport to the OR, to facilitate the insertion of an intravenous (IV) cannula. Premedication included intramuscular (IM) midazolam at 0.3 mg/kg and atropine at 0.02 mg/kg, administered 15 minutes before transportation to the operating room (OR). Upon arrival in the OR, standard monitoring equipment will be applied, including electrocardiography, non-invasive blood pressure, and pulse oximetry. The anesthesia machine and all necessary equipment and medications for general anesthesia (GA) will be prepared for each patient. The IV cannula will be inserted, secured and checked with a saline flush. IV midazolam at a dose of 0.1 mg/kg will be given at the time of spinal anesthesia administration to ensure immobility during the procedure.

A Pediatric Analog Sedation Score (PASS) will be used to evaluate sedation levels during the procedure as well as intraoperatively, where a score of 0 = no sedation, 1 = slightly sedated, 2 = moderately sedated, 3 = well sedated, and 4 = heavily sedated. The target sedation score is 1, indicating minimal sedation. The child will be positioned in the lateral decubitus position, and under strict aseptic conditions, the lumbar region will be sterilized using Betadine. A lumbar puncture will be performed at the L4-L5 interspace (Tuffier's line) using a 2.5-inch 22-gauge Quincke needle by an experienced anesthesiologist. A formula will be used to estimate the distance from skin to subarachnoid space (mm) = [2 × weight (kg)]+ 7(mm). This will be used as a guide to reduce chances of inserting the spinal needle too deep. Two attempts at obtaining a free flow of cerebrospinal fluid (CSF) will be allowed; if unsuccessful, the patient will be excluded from the study and switched to GA. A new attempt involves removing the needle and reinserting it. The calculated dose of hyperbaric bupivacaine 0.5% (Trade name: Sunnypivacaine, Manufacturer: Sunny Pharmaceuticals, Country: Egypt) will be aspirated and administered via a 3-ml syringe.

Group A:

Hyperbaric bupivacaine 0.5% will be administered based on weight:

  • 0.4 mg/kg (0.08 ml/kg) for children weighing 5-15 kg
  • 0.3 mg/kg (0.06 ml/kg) for children weighing >15 kg.

Group B:

Hyperbaric bupivacaine 0.5% will be calculated using Partha formula by dividing the child's age in years by 5. The resultant figure will be considered to be the dose of Bupivacaine in ml. If the number of months after the completion of a year in age is more than 6 months, the child's age will be noted to be the year older.

After obtaining free flow of CSF, and negative aspiration test for blood, the local anesthetic will be administered slowly. Then, the child will be placed in a supine position with a small pillow under the head. IV fluids will be administered at a rate of 4 ml/kg/hr. Sensory and motor levels will be assessed every minute for the first 5 minutes. The adequacy of the block will be determined by the lack of response to a firm skin pinch at the dermatomal level. The peak sensory level will be determined when the dermatomal level remained unchanged in at least two consecutive assessments. If the patient reported pain, the block will be considered failed, and they are excluded from the study. Motor blockade at or above the L1 level will be tested using superficial abdominal reflexes. After a maximum of ten minutes after spinal anesthesia, the target peak sensory level should be at least T10, and the Bromage score should be 3, indicating a complete motor block. Only then the surgery will be proceeded. Iff inadequate sensory or motor block are observed (e.g., peak sensory level below T10 or Bromage score <3), GA will be administered, and the failure will be documented.

Being tested
Spinal Anesthesia with Bupivacaine

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Spinal Anesthesia with BupivacaineProcedure or surgery

    Group A (n=30) will receive spinal anesthesia according to the weight-based dosing calculation of bupivacaine.

  • Spinal Anesthesia with BupivacaineProcedure or surgery

    Group B (n=30) will receive spinal anesthesia according to the age-based dosing calculation of bupivacaine.

Study groups in NCT07035184
Study groupRoleWhat they receive
Group A: weight-based formula groupActive comparatorChildren will receive spinal anesthesia according to the weight-based dosing calculation of Hyperbaric bupivacaine 0.5% as following: 0.4 mg/kg (0.08 ml/kg) for children weighing 5-15 kg or 0.3 mg/kg (0.06 ml/kg) for children weighing >15 kg
Receives: Procedure: Spinal Anesthesia with Bupivacaine
Group B: Age-based formula groupActive comparatorChildren will receive spinal anesthesia according to the age-based dosing calculation of bupivacaine. Hyperbaric bupivacaine 0.5% will be calculated using Partha formula by dividing the child's age in years by 5. The resultant figure will be considered to be the dose of Bupivacaine in ml. If the number of months after the completion of a year in age is more than 6 months, the child's age will be noted to be the year older.
Receives: Procedure: Spinal Anesthesia with Bupivacaine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The peak sensory level

    The peak sensory level will be assessed 5 minutes after intrathecal bupivacaine injection, and evaluated by a firm skin pinch.

    Measured: Assessed 5 minutes after intrathecal bupivacaine injection, and evaluated by a firm skin pinch up to 30 minutes after subarachnoid block

Secondary outcomes (7)
  1. Time of completion of spinal block

    Time in seconds to complete block administration starting at the time of application of Betadine on the site of lumbar puncture to the time at which the patient is placed on their back after administration of spinal anesthesia

    Measured: starts immediately at the time of application of Betadine on the site of lumbar puncture to the time at which the patient is placed on their back after immediately administering the spinal anesthesia

  2. Duration of spinal block

    Duration of block: the time in minutes from achieving peak sensory and motor level to the onset of pain or the movement of the legs.

    Measured: starts immediately after achieving a peak sensory and motor levels and eds immediately by the onset of perioperative pain or movement of legs

  3. Postoperative pain score

    Postoperative pain score will be recorded using the Face, Legs, Activity, Cry, and Consolability (FLACC) Scale at 2, 4, and 6 hours from block administration. The scale consists of five categories: Face, Legs, Activity, Cry, and Consolability, each of which is scored from 0 to 2. A score of 0 represents no pain or distress, while a score of 2 indicates significant discomfort or distress.

    Measured: Scale will be assessed postoperatively at 2 hours, 4 hours, and 6 hours from block administration.

  4. The need for rescue analgesia in PACU

    The need for rescue analgesia in PACU: IV Pethidine 1 mg/kg will be administered once for a pain score of 6 or higher using FLACC scale

    Measured: Postoperatively at 2 hours after spinal block and up to 1 hour postoperatively

  5. Incidence of failure of spinal block

    Incidence of failure of spinal block defined by a failure to reach sensory level of T10 and modified Bromage score of 3; therefore, requiring the switch to GA.

    Measured: 20 minutes after local anesthetic administration until 30 minutes after local anesthetic administration

  6. Complications related to anesthesia

    Complications related to anesthesia, such as vomiting, shivering, post dural puncture headache, and any manifestation suggestive of neurological injury, will be recorded.

    Measured: started immediately after lumbar puncture and followed up for 2 hours postoperatively

  7. Incidence of intraoperative complications

    Incidence of hypotension and or bradycardia defined as and 20% decrease from baseline values

    Measured: Started immediately after spinal block until the end of surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jun 2025
  2. Study start1 Aug 2025 (estimated)
  3. Primary completion1 Oct 2025 (estimated)
  4. Study completion15 Oct 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Outcomes assessor
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07035184
Sponsor's protocol ID
"MS-503-2024"
Status last verified
Dec 2024
First submitted
7 Jun 2025
Last updated
25 Jun 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Only IPD used in the results publications

Publications

  • Crellin DJ, Harrison D, Santamaria N, Huque H, Babl FE. The Psychometric Properties of the FLACC Scale Used to Assess Procedural Pain. J Pain. 2018 Aug;19(8):862-872. doi: 10.1016/j.jpain.2018.02.013. Epub 2018 Mar 15.

    PubMed 29551662
  • Srinivasan P, Saravanan B, Kulandayan I, Thambidurai S, Mahalakshmi V. Evaluation of efficacy and safety of age-based intrathecal dosing of 0.5% hyperbaric bupivacaine in the paediatric age group. J Clin Diagn Res. 2020;14(8):29-31.

  • Troncin R, Dadure C. Paediatric spinal anaesthesia. management. 2009;4(3):8-12.

  • Elsharkawi NG. Simple pediatric analog sedation score (PASS). Anesth Analg. 1999 Jan;88(1):227. doi: 10.1097/00000539-199901000-00043. No abstract available.

    PubMed 9895098
  • Luca E, Schipa C, Cambise C, Sollazzi L, Aceto P. Implication of age-related changes on anesthesia management. Saudi J Anaesth. 2023 Oct-Dec;17(4):474-481. doi: 10.4103/sja.sja_579_23. Epub 2023 Aug 18.

    PubMed 37779561
  • Hebbes CP, Thompson JP. Pharmacokinetics of anaesthetic drugs at extremes of body weight. BJA Educ. 2018 Dec;18(12):364-370. doi: 10.1016/j.bjae.2018.09.001. Epub 2018 Oct 26. No abstract available.

    PubMed 33456803
  • Visavakul O, Leurcharusmee P, Pipanmekaporn T, Khorana J, Patumanond J, Phinyo P. Effective Dose Range of Intrathecal Isobaric Bupivacaine to Achieve T5-T10 Sensory Block Heights for Elderly and Overweight Patients: An Observational Study. Medicina (Kaunas). 2023 Mar 1;59(3):484. doi: 10.3390/medicina59030484.

    PubMed 36984485
  • Parthasarathy S, Senthilkumar T. Age-based Local Anesthetic Dosing in Pediatric Spinal Anesthesia: Evaluation of a New Formula - A Pilot Study in Indian Patients. Anesth Essays Res. 2017 Jul-Sep;11(3):627-629. doi: 10.4103/aer.AER_246_16.

    PubMed 28928560
  • Lonnqvist PA. Spinal anaesthesia in children: A narrative review. Best Pract Res Clin Anaesthesiol. 2023 Jun;37(2):133-138. doi: 10.1016/j.bpa.2023.01.002. Epub 2023 Feb 7.

    PubMed 37321762
  • Jefferson FA, Findlay BL, Handlogten KS, Gargollo PC, Warner LL, Woodbury JM, Haile DT, Granberg CF. Spinal anesthesia in infants undergoing urologic surgery duration greater than 60 minutes. J Pediatr Urol. 2022 Dec;18(6):786.e1-786.e7. doi: 10.1016/j.jpurol.2022.07.003. Epub 2022 Jul 14.

    PubMed 35945145
  • Verma D, Naithani U, Gokula C, Harsha. Spinal anesthesia in infants and children: A one year prospective audit. Anesth Essays Res. 2014 Sep-Dec;8(3):324-9. doi: 10.4103/0259-1162.143124.

    PubMed 25886329
  • Heydinger G, Tobias J, Veneziano G. Fundamentals and innovations in regional anaesthesia for infants and children. Anaesthesia. 2021 Jan;76 Suppl 1:74-88. doi: 10.1111/anae.15283.

    PubMed 33426659

Questions about this trial

What is this clinical trial studying?

A study testing Spinal Anesthesia with Bupivacaine in people with Pediatrics and Spinal Aneshtesia, run by Cairo University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 25 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Hany M.EH Mohammed, MD (+201003066806, oblfollower_2001@yahoo.com, hany.elhadi@kasralainy.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The peak sensory level (time frame: Assessed 5 minutes after intrathecal bupivacaine injection, and evaluated by a firm skin pinch up to 30 minutes after subarachnoid block). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07035184, which also lists 12 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in